. . "In fact, in postmenopausal women there is an increase in body weight and a different fat distribution induced by hormonal changes; in this context, peg-interferon ??-2A has a predominant distribution in plasma and liver and thus it may have a lower bioavailability compared to peg-interferon ??-2B, which also distributes within extrahepatic tissues, such as cytokine-producing visceral fat tissue." . .